Development history
Overview of Leecan History Corporate Culture Honor Responsibility
View More
2026
2025.01Sustainable Leecan Industry Quality Year Construction (Consolidation and Deepening Year)
2025.01Fumarate Fumatrol Inhalation Solution Received Approval!
2025.05Good news! Hefei Leecan Pharmaceutical has been approved for the "Drug Production License" A certificate!
2025.09Good news! Two specifications of ipratropium bromide solution for inhalation have obtained drug production approval!
2025.11Good news! Nanjing Leecan Pharmaceutical has obtained the certificate of high-tech enterprise!
2025.12Good news! Nanjing Leecan Pharmaceutical Co., Ltd. has obtained a specialized and special new enterprise!
2025
2025.01
Sustainable Leecan Industry Quality Year Construction (Consolidation and Deepening Year)
2025.01
Fumarate Fumatrol Inhalation Solution Received Approval!
2025.05
Good news! Hefei Leecan Pharmaceutical has been approved for the "Drug Production License" A certificate!
2025.09
Good news! Two specifications of ipratropium bromide solution for inhalation have obtained drug production approval!
2025.11
Good news! Nanjing Leecan Pharmaceutical has obtained the certificate of high-tech enterprise!
2025.12
Good news! Nanjing Leecan Pharmaceutical Co., Ltd. has obtained a specialized and special new enterprise!
2024.04Terbutaline Sulfate Nebulised Inhalation Solution Receives Approval
2024.06Budesonide Suspension for Inhalation, Salbutamol Sulfate Solution for Inhalation Receive Approvals
2024.10Hefei Leecan Co., Ltd. is selected as a potential unicorn enterprise in Hefei in 2024
2024.12Compound ipratropium bromide solution for inhalation has received approval
2024.12Injection of Bendamustine Hydrochloride Received Approval
2024
2024.01
Initiate the Quality Year Construction of Leecan Industry (Consolidate Foundation Year)
2024.04
Terbutaline Sulfate Nebulised Inhalation Solution Receives Approval
2024.06
Budesonide Suspension for Inhalation, Salbutamol Sulfate Solution for Inhalation Receive Approvals
2024.10
Hefei Leecan Co., Ltd. is selected as a potential unicorn enterprise in Hefei in 2024
2024.12
Compound ipratropium bromide solution for inhalation has received approval
2024.12
Injection of Bendamustine Hydrochloride Received Approval
2023.04The first self-developed product completed the research and development and has registered, and Hefei base foundation stone laying.
2023.09LDP0105 declared production, Hefei headquarters triumphantly topped out
2023
2023.01
Initiate the standardization year construction of Leecan Industry
2023.04
The first self-developed product completed the research and development and has registered, and Hefei base foundation stone laying.
2023.07
LDP0501/LDP0502 declared production
2023.09
LDP0105 declared production, Hefei headquarters triumphantly topped out
2023.10
LDP0107 declared production
2022.07Completion of the accelerator production base and move-in
2022
2022.04
Signing of key projects in Nanjing
2022.07
Completion of the accelerator production base and move-in
2022.08
Hefei Headquarters Base Project Signing
2022.09
LDP0103 declared for production and obtained Drug Manufacturing Leecan Certificate B
2022.10
First self-developed product completes pre-BE
2022.11
LDP0102 declared for production and obtained Certificate A of Pharmaceutical Manufacturing Leecan
2022.12
The first self-developed product to carry out official BE
2021.11The experimental area of the Zhongdan Park was put into operation
2021.12Accelerator production base started
2021
2021.05
Nanjing Leecan was incorporated
2021.06
Completion of PRE-A round of financing
2021.08
Laboratory construction at China-Danish Park launched
2021.11
The experimental area of the Zhongdan Park was put into operation
2021.12
Accelerator production base started
025-58181716
Friendship link：
Baidu
Website Map | Privacy Policy | Legal Notice |
© Copyright 2021 南京力成药业有限公司 版权所有 All Rights Reserved.
苏ICP备2024114006号